Cart
sales@molnova.com
BMS-813160
CAS No. 1286279-29-5
BMS-813160( —— )
Catalog No. M17924 CAS No. 1286279-29-5
BMS-813160 is the first dual CCR2/CCR5 antagonist to enter Clinical development for cardiovascular.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 141 | In Stock |
|
| 5MG | 132 | In Stock |
|
| 10MG | 187 | In Stock |
|
| 25MG | 341 | In Stock |
|
| 50MG | 555 | In Stock |
|
| 100MG | 792 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 1609 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBMS-813160
-
NoteResearch use only, not for human use.
-
Brief DescriptionBMS-813160 is the first dual CCR2/CCR5 antagonist to enter Clinical development for cardiovascular.
-
DescriptionBMS-813160 is the first dual CCR2/CCR5 antagonist to enter Clinical development for cardiovascular.(In Vitro):BMS-813160 binds with CCR2, CCR5, CCR1, CCR4 and CXCR2 with IC50s of 6.2 nM, 3.6 nM, ＞25 μM, ＞40 μM and ＞40 μM, respectively.BMS-813160 shows activities to CCR2 CTX, CCR2 CD11b, CCR5 CTX and CCR5 CD11b with IC50s of 0.8, 4.8, 1.1 and 5.7 nM, respectively.(In Vivo):BMS-813160 (10-160 mg/kg; p.o. twice a day for two days) inhibits the migration of inflammatory monocytes and macrophages in mouse thioglycollate-induced peritonitis model, and shows excellent oral bioavailability.
-
In VitroBMS-813160 binds with CCR2, CCR5, CCR1, CCR4 and CXCR2 with IC50s of 6.2 nM, 3.6 nM, ＞25 μM, ＞40 μM and ＞40 μM, respectively.BMS-813160 shows activities to CCR2 CTX, CCR2 CD11b, CCR5 CTX and CCR5 CD11b with IC50s of 0.8, 4.8, 1.1 and 5.7 nM, respectively.
-
In VivoBMS-813160 (10-160 mg/kg; p.o. twice a day for two days) inhibits the migration of inflammatory monocytes and macrophages in mouse thioglycollate-induced peritonitis model, and shows excellent oral bioavailability. Animal Model:Human-CCR2 knock-in C57BL/6 male mice with thioglycollate injectionDosage:10, 50 and 160 mg/kg Administration:Oral gavage; 10-160 mg/kg twice a day; for two days Result:Dose-dependently reduced inflammatory monocyte and macrophage infiltration in the peritoneum.
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetPotassium Channel
-
RecptorCCR2|CCR5
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1286279-29-5
-
Formula Weight484.64
-
Molecular FormulaC25H40N8O2
-
Purity>98% (HPLC)
-
SolubilityDMSO : 25 mg/mL 51.58 mM;
-
SMILESCC(C)(C)N[C@@H]1CC[C@@H]([C@H](NC(C)=O)C1)N4CC[C@H](Nc2ncnc3cc(nn23)C(C)(C)C)C4=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Norman P. et al. A dual CCR2/CCR5 chemokine antagonist, BMS-813160? Evaluation of WO2011046916. Expert Opin Ther Pat. 2011 Dec;21(12):1919-24.
molnova catalog
related products
-
Margatoxin
Potent KV1.3 channel blocker (IC50 = 36 pM). Displays no effect at calcium-activated channels. Reduces VEGF-induced transmembrane calcium influxes and nitric oxide production in human endothelial cells.
-
Potassium Channel Ac...
Potassium Channel Activator 1 can be used in studies about the treatment of disorders or conditions wherein the dopaminergic system is disrupted such as mood disorders ADHD, schizophrenia, and other psychotic states.
-
Glibornuride
Glibornuride is a blocker of ATP-sensitive K+ channel(pKi: 5.75). Glibornuride inhibits high affinity [3H]-glibenclamide binding with the potencies expected from their K+ channel activity.
